In connection with the subscription period for Prolight Diagnostics AB’s (Prolight’ or the ‘Company’) rights issue of shares, which runs between June 16 and June 30, 2025, the Company invites shareholders and external investors to a digital investor meeting. The meeting will be held via Microsoft Teams on June 24, 2025, at 14:00 CEST.
During the meeting, Prolight’s CEO Ulf Bladin will present the company’s recent progress, including the first results from the whole blood study at St Thomas’ Hospital in London, what the results enable and upcoming milestones. During the investor meeting, there will be an opportunity to ask questions directly via the chat function.
Registration
Please register by emailing corporatefinance@mangold.se as soon as possible, no later than Monday, June 23, 2025. Questions can be submitted in advance and will be answered during the Q&A session if time allows. It will also be possible to ask questions live during the meeting.
More information about the rights issue is available on Prolights website.
Indicative timetable
| June 16 – June 25, 2025 | Trading in subscription rights (TR) on NGM |
| June 16 – June 30, 2025 | Subscription period in the Rights Issue |
| June 16 – July 16, 2025 | Expected trading in paid subscribed shares (BTA) on NGM |
| July 2, 2025 | Estimated date for announcement of issue outcome |
